Form 4: Rocket Pharmaceuticals CFO Aaron Ondrey Reports Stock and Option Transactions

Chief Financial Officer of Rocket Pharmaceuticals, Aaron Ondrey, reports the acquisition of restricted stock units and stock options.

Summary

• Aaron Ondrey, the Chief Financial Officer of Rocket Pharmaceuticals, reported transactions involving the company's securities.
• On April 1, 2024, Ondrey acquired 46,781 Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.
• One-third of these RSUs will vest on April 1, 2025, with the remaining shares vesting in equal quarterly installments over the following two years.
• Also on April 1, 2024, Ondrey acquired options to purchase 69,337 shares of Rocket Pharmaceuticals' common stock at an exercise price of $26.72.
• These options also vest over a three-year period, with one-third vesting on April 1, 2025, and the remainder vesting in equal quarterly installments over the subsequent two years, contingent upon continued employment.

Sentiment

Score: 6

Explanation: The document is a routine filing related to executive compensation. It doesn't contain information that would significantly impact investor sentiment positively or negatively.

Positives

• The granting of RSUs and stock options to the CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The vesting schedule for the RSUs and stock options extends over the next three years, indicating a long-term incentive structure.

Industry Context

Stock options and RSU grants are common compensation practices in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules described are typical, often spanning three to four years to encourage long-term commitment.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they relate to executive compensation and alignment of interests.
• Employees may view the stock option grants as a positive sign of the company's commitment to its leadership.

Key Dates